{"id":10189,"date":"2026-04-16T04:36:51","date_gmt":"2026-04-16T03:36:51","guid":{"rendered":"https:\/\/tanja7.com\/en\/10189"},"modified":"2026-04-16T04:36:51","modified_gmt":"2026-04-16T03:36:51","slug":"blinklab-secures-a17-5-million-to-obtain-fda-clearance-for-autism-diagnostics-and-propel-adhd-trials-forward","status":"publish","type":"post","link":"https:\/\/tanja7.com\/en\/10189","title":{"rendered":"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward"},"content":{"rendered":"<p><a href=\"https:\/\/smallcaps.com.au\/stocks\/asx-bb1\">BlinkLab (ASX: BB1)<\/a> has conducted an oversubscribed <strong>A$17.5 million<\/strong> placement at <strong>A$0.65 per share<\/strong> to fund trials for its autism diagnostic aid (<strong>Dx1<\/strong>) and advance US <strong>ADHD<\/strong> clinical studies.<\/p>\n<p>The placement issued <strong>26,923,077<\/strong> new fully-paid ordinary shares, with directors committing to <strong>A$200K<\/strong> worth of shares.<\/p>\n<p>The proceeds will be primarily directed towards completing pivotal <strong>FDA 510(k)<\/strong> clearance trials for its autism diagnostic aid (<strong>Dx1<\/strong>) and accelerating <strong>CE<\/strong> marking and <strong>EU MDR<\/strong> processes for <strong>Dx1<\/strong> in Europe.<\/p>\n<p>The funds will also launch and advance BlinkLab&#8217;s US <strong>ADHD<\/strong> program using its <strong>Dx2<\/strong> platform, including initiating the <strong>FDA 510(k)<\/strong> trial process for <strong>ADHD<\/strong>.<\/p>\n<p>Additionally, working capital will support ongoing operations, platform development, and extending the company&#8217;s patent portfolio.<\/p>\n<h2>Morocco Program Validation and Expansion<\/h2>\n<p>In a significant development, BlinkLab&#8217;s <strong>Dx1<\/strong> has been selected for Morocco&#8217;s nationwide, government-funded autism screening initiative.<\/p>\n<p>This program, commencing in <strong>April 2026<\/strong>, will see early autism screening start at <strong>18 months<\/strong> of age across outpatient and hospital settings in Morocco.<\/p>\n<p>The Moroccan government and the <strong>Foundation Mohammed V for Solidarity<\/strong> will fund all program-related costs, including clinical rollout and implementation, with BlinkLab retaining ownership of the data generated by the program and expecting no material capital expenditure.<\/p>\n<p>This real-world deployment is considered to complement the company&#8217;s ongoing <strong>FDA<\/strong> registrational trials, with commercial terms for Morocco to be revisited after any future <strong>FDA<\/strong> clearance.<\/p>\n<h2>Autism Dx1 FDA Pathway Progress<\/h2>\n<p>BlinkLab&#8217;s <strong>FDA 510(k)<\/strong> pivotal validation program for <strong>Dx1<\/strong> has commenced, with the first participant successfully enrolled and completing initial testing.<\/p>\n<p>This double-blinded, multi-centre study is designed to generate pivotal clinical and usability evidence for a targeted <strong>FDA<\/strong> submission by <strong>end-2026<\/strong>.<\/p>\n<p>Prior pilot data for <strong>Dx1<\/strong> has reportedly exceeded <strong>FDA<\/strong>-agreed performance thresholds, indicating the diagnostic aid is approaching late-stage regulatory and commercial readiness.<\/p>\n<p>The study is being led and conducted by <strong>IQVIA-MCRA<\/strong> to ensure adherence to protocols and data quality standards.<\/p>\n<p>The recently secured capital will also initiate the <strong>FDA 510(k)<\/strong> trial process for <strong>ADHD<\/strong> using BlinkLab&#8217;s <strong>Dx2<\/strong> platform, expanding the company&#8217;s diagnostic pipeline beyond autism and leveraging its existing smartphone-based platform infrastructure for the US clinical program expansion into <strong>ADHD<\/strong>.<\/p>\n<p><a href=\"https:\/\/smallcaps.com.au\/article\/blinklab-raises-a-17-5m-to-fund-fda-autism-diagnostic-clearance-and-advance-adhd-trials\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BlinkLab (ASX: BB1) has conducted an oversubscribed A$17.5 million placement at A$0.65 per share to fund trials for its autism diagnostic aid (Dx1) and advance US ADHD clinical studies. The placement issued 26,923,077 new fully-paid ordinary shares, with directors committing to A$200K worth of shares. The proceeds will be primarily directed towards completing pivotal FDA [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10190,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_post_was_ever_published":false},"categories":[111],"tags":[],"tmauthors":[],"class_list":["post-10189","post","type-post","status-publish","format-standard","has-post-thumbnail","category-headlines"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward - Tanja7 English<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tanja7.com\/en\/10189\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward - Tanja7 English\" \/>\n<meta name=\"twitter:description\" content=\"BlinkLab (ASX: BB1) has conducted an oversubscribed A$17.5 million placement at A$0.65 per share to fund trials for its autism diagnostic aid (Dx1) and advance US ADHD clinical studies. The placement issued 26,923,077 new fully-paid ordinary shares, with directors committing to A$200K worth of shares. The proceeds will be primarily directed towards completing pivotal FDA [&hellip;]\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tanja7\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189\"},\"author\":{\"name\":\"Tanja7\",\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/#\\\/schema\\\/person\\\/effb4ebf2e0b9c32a577250bf6751e3e\"},\"headline\":\"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward\",\"datePublished\":\"2026-04-16T03:36:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189\"},\"wordCount\":372,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tanja7.com\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/small.jpeg\",\"articleSection\":[\"headlines\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/tanja7.com\\\/en\\\/10189#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189\",\"url\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189\",\"name\":\"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward - Tanja7 English\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tanja7.com\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/small.jpeg\",\"datePublished\":\"2026-04-16T03:36:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/#\\\/schema\\\/person\\\/effb4ebf2e0b9c32a577250bf6751e3e\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tanja7.com\\\/en\\\/10189\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189#primaryimage\",\"url\":\"https:\\\/\\\/tanja7.com\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/small.jpeg\",\"contentUrl\":\"https:\\\/\\\/tanja7.com\\\/en\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/small.jpeg\",\"width\":400,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/10189#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tanja7.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/tanja7.com\\\/en\\\/\",\"name\":\"Tanja7 English\",\"description\":\"All the news\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tanja7.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tanja7.com\\\/en\\\/#\\\/schema\\\/person\\\/effb4ebf2e0b9c32a577250bf6751e3e\",\"name\":\"Tanja7\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/34bc74869a70de3f3f92c455d66f4b6f7201a2b8288d8676782f0324aa6c1d0a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/34bc74869a70de3f3f92c455d66f4b6f7201a2b8288d8676782f0324aa6c1d0a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/34bc74869a70de3f3f92c455d66f4b6f7201a2b8288d8676782f0324aa6c1d0a?s=96&d=mm&r=g\",\"caption\":\"Tanja7\"},\"sameAs\":[\"https:\\\/\\\/tanja7.com\\\/en\"],\"url\":\"https:\\\/\\\/tanja7.com\\\/en\\\/author\\\/admin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward - Tanja7 English","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tanja7.com\/en\/10189","twitter_card":"summary_large_image","twitter_title":"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward - Tanja7 English","twitter_description":"BlinkLab (ASX: BB1) has conducted an oversubscribed A$17.5 million placement at A$0.65 per share to fund trials for its autism diagnostic aid (Dx1) and advance US ADHD clinical studies. The placement issued 26,923,077 new fully-paid ordinary shares, with directors committing to A$200K worth of shares. The proceeds will be primarily directed towards completing pivotal FDA [&hellip;]","twitter_misc":{"Written by":"Tanja7","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tanja7.com\/en\/10189#article","isPartOf":{"@id":"https:\/\/tanja7.com\/en\/10189"},"author":{"name":"Tanja7","@id":"https:\/\/tanja7.com\/en\/#\/schema\/person\/effb4ebf2e0b9c32a577250bf6751e3e"},"headline":"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward","datePublished":"2026-04-16T03:36:51+00:00","mainEntityOfPage":{"@id":"https:\/\/tanja7.com\/en\/10189"},"wordCount":372,"commentCount":0,"image":{"@id":"https:\/\/tanja7.com\/en\/10189#primaryimage"},"thumbnailUrl":"https:\/\/tanja7.com\/en\/wp-content\/uploads\/2026\/04\/small.jpeg","articleSection":["headlines"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/tanja7.com\/en\/10189#respond"]}]},{"@type":"WebPage","@id":"https:\/\/tanja7.com\/en\/10189","url":"https:\/\/tanja7.com\/en\/10189","name":"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward - Tanja7 English","isPartOf":{"@id":"https:\/\/tanja7.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tanja7.com\/en\/10189#primaryimage"},"image":{"@id":"https:\/\/tanja7.com\/en\/10189#primaryimage"},"thumbnailUrl":"https:\/\/tanja7.com\/en\/wp-content\/uploads\/2026\/04\/small.jpeg","datePublished":"2026-04-16T03:36:51+00:00","author":{"@id":"https:\/\/tanja7.com\/en\/#\/schema\/person\/effb4ebf2e0b9c32a577250bf6751e3e"},"breadcrumb":{"@id":"https:\/\/tanja7.com\/en\/10189#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tanja7.com\/en\/10189"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tanja7.com\/en\/10189#primaryimage","url":"https:\/\/tanja7.com\/en\/wp-content\/uploads\/2026\/04\/small.jpeg","contentUrl":"https:\/\/tanja7.com\/en\/wp-content\/uploads\/2026\/04\/small.jpeg","width":400,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/tanja7.com\/en\/10189#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tanja7.com\/en\/"},{"@type":"ListItem","position":2,"name":"BlinkLab Secures A$17.5 Million to Obtain FDA Clearance for Autism Diagnostics and Propel ADHD Trials Forward"}]},{"@type":"WebSite","@id":"https:\/\/tanja7.com\/en\/#website","url":"https:\/\/tanja7.com\/en\/","name":"Tanja7 English","description":"All the news","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tanja7.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tanja7.com\/en\/#\/schema\/person\/effb4ebf2e0b9c32a577250bf6751e3e","name":"Tanja7","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/34bc74869a70de3f3f92c455d66f4b6f7201a2b8288d8676782f0324aa6c1d0a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/34bc74869a70de3f3f92c455d66f4b6f7201a2b8288d8676782f0324aa6c1d0a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/34bc74869a70de3f3f92c455d66f4b6f7201a2b8288d8676782f0324aa6c1d0a?s=96&d=mm&r=g","caption":"Tanja7"},"sameAs":["https:\/\/tanja7.com\/en"],"url":"https:\/\/tanja7.com\/en\/author\/admin"}]}},"jetpack_featured_media_url":"https:\/\/tanja7.com\/en\/wp-content\/uploads\/2026\/04\/small.jpeg","_links":{"self":[{"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/posts\/10189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/comments?post=10189"}],"version-history":[{"count":0,"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/posts\/10189\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/media\/10190"}],"wp:attachment":[{"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/media?parent=10189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/categories?post=10189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/tags?post=10189"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/tanja7.com\/en\/wp-json\/wp\/v2\/tmauthors?post=10189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}